AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
suramab, a new pharmaceutical compound with antiangiogenic effects
Summary
This can be seen in the patent file
Technology Benefits
Suramab is the brand name of a new combination of drugs made up of suramin and bevacizumab. Suramab has antiangiogenic properties that can be applied to oncological and ophthalmological diseases.
The european patent (EP 2186529 B1) was granted in March 2012.
The US patent is still pending
Application No.
MX2008000104
Coverage Areas
Great Britain, Ireland, Sweden, Denmark, The Netherland, Germany, Spain, France
Goods and Services
License agreement
Patent Information
Issued patent
Country/Region
Argentina
For more information, please click Here
